Regeneron teams with gene therapy pioneer James Wilson, adapting its Covid-19 antibody cocktail to an AAV-based nasal spray
Gene therapy pioneer James Wilson is applying his knowledge and experience in the field to a new frontier: the Covid-19 pandemic.
Wilson and his colleagues at the University of Pennsylvania have signed a collaboration agreement with antibody star Regeneron $REGN to combine the biotech’s Covid-19 antibody cocktail with a nasal spray-based AAV delivery platform. The research could hit the clinic early next year, with the pair aiming to apply for an IND after validating the antibodies’ effectiveness in an animal model challenge study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.